CymaBay Therapeutics Earning Date (CBAY)

USA |NASDAQ |USD

CBAY Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 10, 2022 Jun 2022 - - $-0.34
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 10, 2022 Jun 2022 - - $0.00

Cymabay Therapeutics's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 2022.

CBAY Earnings Date & History Chart

CBAY Earnings & Revenue Forecast

CBAY Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 8 $-1.39 $-1.57 $-1.05

CBAY Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-1.39 $-1.15 $-1.14

CBAY Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 7 $4.29M $0.00 $30.00M

CBAY Earnings Date & Revenue History

CBAY Earnings History

|
Show More
Show More

CBAY Revenue History

|
Show More
Show More

Cymabay Therapeutics Next Earnings Date & Report

CBAY Next Earnings Date & Report Preview: Jun 2022 (FQ)

CBAY's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 30, 2022.

Cymabay Therapeutics Previous Earnings Dates & Reports

CBAY Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Cymabay Therapeutics's previous earnings date was May 11, 2022 for its fiscal quarter ended Mar 31, 2022.

CBAY Previous Earnings Date & Report Recap: Dec 2020 (FY)

Cymabay Therapeutics's previous annual earnings date was Mar 25, 2021 for its fiscal year ended Dec 31, 2020.

CBAY's earnings per share (EPS) was $-0.75, missing the consensus analysts forecast of $-0.71 by 5.63% , and higher than the previous year's EPS (Dec 2019) by -48.42%.

Revenues were $0.00.

The company reported a net income of $-50.99M.

Cymabay Therapeutics reported a free cash flow of $-44.75M for its fiscal year, compared to $-98.23M a year ago.

The company ended the fiscal year with $1.74M in total debt, a decrease of -18.88% compared to the previous year.